No Data
No Data
Q4 2024 Fulcrum Therapeutics Inc Earnings Call
Earnings Call Summary | Fulcrum Therapeutics(FULC.US) Q4 2024 Earnings Conference
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $14
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial
Fulcrum Therapeutics | 10-K: FY2024 Annual Report